

Søgeprotokol for Nationale Kliniske Retningslinjer (120915/TFF)

Projekttitel/aspekt	NKR for psoriasis
Kontakt Fagkonsulent /projektleder	
Kontakt Søgesepecialisten	Tove Faber Frandsen, Videncentret, Odense Universitetshospital
Senest opdateret	

Baggrund	PICOs 1-9
Søgetermer	Se søgestrategierne under de enkelte PICOs
Inklusions- og eksklusionskriterier	Sprog: Engelsk, dansk, norsk og svensk

Informationskilder

Database	Interface	Dato for søgning
Medline	OVID	Juni-august 2015
EMBASE	OVID	Juni-august 2015

Note

- Søgetermer og inklusions- og eksklusionskriterier er tilpasset de enkelte databaser.
- Dubletter er så vidt muligt frasorteret ved hjælp af RefWorks. De fundne referencer overføres til Covidence (referenceværktøj)
- Fuldtekster præsenteres i Covidence i pdf-format
- Søgestrategi for hver enkelt database præsenteres – hvis muligt vises det eksplicit hvor mange referencer den enkelte søgestreng genererer

Søgestrategi

PICO 1

Informationskilder

Database	Interface	Dato for søgning
Medline	OVID	7. juli 2015
EMBASE	OVID	7. juli 2015

Medline

ID	term(s)	results
1	exp Psoriasis/ or psoria*.mp.	39839
2	(therapy adj3 failure*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	9240
3	exp Treatment Failure/	28048
4	(treatment adj3 failure*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	54251
5	(drug adj3 failure*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	2055
6	(rate* adj3 failure*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	18526
7	(drug adj3 survival*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	1104
8	discontin*.mp.	94424
9	(lack* adj3 effic*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	5892
10	2 or 3 or 4 or 5 or 6 or 7 or 8 or 9	177359
11	1 and 10	963
12	budesonide.mp. or exp Budesonide/	4935
13	(vitamin adj d adj2 analogue\$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	821
14	(vitamin adj d adj2 derivative\$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	325
15	exp Calcitriol/ or calcipotriol.mp.	13314
16	calcipotriene.mp.	864
17	dovonex.mp.	26

18	dovobet.mp.	28
19	tacalcitol.mp.	145
20	curatoderm.mp.	2
21	exp Calcitriol/ or calcitriol.mp.	18507
22	silkis.mp. or exp Calcitriol/	13145
23	maxacalcitol.mp.	271
24	exp Adrenal Cortex Hormones/ or adrenal cortex hormon*.mp.	345485
25	corticosteroid\$.mp.	80857
26	cortico steroid\$.mp.	246
27	hydrocortisone.mp. or exp Hydrocortisone/	69590
28	dioderm.mp.	3
29	efcortelan.mp.	4
30	hydrocortisyl.mp.	1
31	mildison.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	0
32	alphaderm.mp.	6
33	locoid.mp.	32
34	alclometasone dipropionate.mp.	35
35	modrasone.mp.	1
36	beclomethasone.mp. or exp Beclomethasone/	3553
37	beclomet\$asone dipropionate.mp.	94
38	propaderm.mp.	4
39	exp Betamethasone/ or betamethasone.mp.	7595
40	betamethasone esters.mp.	9
41	betacap.mp.	3
42	betnovate.mp.	32
43	diprosone.mp.	21
44	diprosalic.mp.	8
45	bettamousse.mp.	2
46	clobetasol propionate.mp. or exp Clobetasol/	1225
47	dermovate.mp.	49
48	clobetasone butyrate.mp.	131
49	eumovate.mp.	13
50	desoximetasone.mp. or exp Desoximetasone/	88
51	desoxymethasone.mp. or exp Desoximetasone/	81
52	stiedex.mp.	0
53	diflucortolone.mp. or exp Diflucortolone/	127
54	nerisone.mp.	7
55	fluocinolone acetonide.mp. or exp Fluocinolone Acetonide/	1527
56	synalar.mp.	47
57	fluocinonide.mp. or exp Fluocinonide/	263
58	metosyn.mp.	11
59	fluocortolone.mp. or exp Fluocortolone/	370
60	ultralanum.mp.	7
61	flurandrenolone.mp. or exp Flurandrenolone/	133
62	fludroxycortid\$.mp.	4

63	haelan.mp.	5
64	fluticasone propionate.mp.	1924
65	cutivate.mp.	6
66	halcinonide.mp. or exp Halcinonide/	77
67	halciderm.mp.	2
68	mometasone furoate.mp.	730
69	elocon.mp.	6
70	exp Triamcinolone Acetonide/ or exp Triamcinolone/ or triamcinolone.mp.	10060
71	adcortyl.mp.	11
72	aureocort.mp.	1
73	tri-adcortyl.mp.	6
74	nystadermal.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	0
75	steroid\$.mp. or exp Steroids/	878752
76	12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75	970046
77	((singl* or doubl* or treb* or tripl*) adj (blind\$3 or mask\$3)).tw.	137213
78	(allocated adj2 random).tw.	728
79	(clin* adj25 trial*).ti,ab.	297458
80	(clinic* adj trial\$1).tw.	239677
81	(double-blind* or random*).af.	1004001
82	clinical trial.pt.	496174
83	clinical trials as topic.sh.	173607
84	clinical* trial*.tw.	239966
85	controlled clinical trial.pt.	89829
86	double blind method.sh.	131189
87	single blind method.sh.	20710
88	double-blind method.sh.	131189
89	single-blind method.sh.	20710
90	drug therapy.fs.	1788414
91	exp clinical trials as topic/	291170
92	exp Research Design/	351980
93	placebo*.tw.	169546
94	placebos.sh.	33060
95	practice guideline.pt.	20360
96	random allocation.sh.	84044
97	random*.ti,ab.	780082
98	random*.tw.	780082
99	Random.af.	268620
100	randomized controlled trial.pt.	399134
101	randomized controlled trials as topic.sh.	98693
102	randomized.ab.	325685
103	randomly allocated.tw.	18833

104	randomly.ab.	234080
105	single-blind method.sh.	20710
106	trial.ab.	337238
107	trial.ti.	140880
108	77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107	3060604
109	case report.tw.	221168
110	letter.pt.	886378
111	historical article.pt.	317993
112	109 or 110 or 111	1413275
113	108 not 112	2881143
114	11 and 76 and 113	152
115	limit 114 to (danish or english or norwegian or swedish)	135

Embase

ID	term(s)	results
1	exp psoriasis/ or psoria*.mp.	68367
2	(therapy adj3 failure*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	12883
3	exp treatment failure/ or Treatment Failure*.mp.	101501
4	(treatment adj3 failure*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	117169
5	(drug adj3 failure*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	23791
6	(rate* adj3 failure*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	24422
7	(drug adj3 survival*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	1743
8	discontinu*.mp.	133888
9	(lack* adj3 effic*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	8521
10	2 or 3 or 4 or 5 or 6 or 7 or 8 or 9	285463
11	1 and 10	2699
12	((singl* or doubl* or treb* or tripl*) adj (blind\$3 or mask\$3)).tw.	177176
13	(allocated adj2 random).tw.	810
14	(clin* adj25 trial*).ti,ab.	398871
15	(clinic* adj trial\$1).tw.	321071
16	(double-blind* or random*).af.	1200898

17	exp "clinical trial (topic)"/	153656
18	exp double blind procedure/ or exp single blind procedure/ or exp triple blind procedure/	143447
19	placebo*.tw.	222157
20	exp placebo/	271775
21	exp randomization/	67141
22	Random.af.	219608
23	random*.tw.	1000251
24	exp "randomized controlled trial (topic)"/	77457
25	randomized.ab.	439026
26	randomly allocated.tw.	22983
27	randomly.ab.	296630
28	trial.ab.	451111
29	trial.ti.	185900
30	exp "controlled clinical trial (topic)"/	80746
31	randomized controlled trial/	378749
32	"randomized controlled trial (topic)"/	77457
33	exp controlled clinical trial/	516057
34	12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33	1842081
35	11 and 34	787
36	limit 35 to (conference abstract or editorial)	246
37	35 not 36	541
38	limit 37 to (danish or english or norwegian or swedish)	515

PICO 2

Informationskilder

Database	Interface	Dato for søgning
Medline	OVID	17. august 2015
EMBASE	OVID	17. august 2015

Medline

ID	term(s)	results
1	(ultraviolet and (therap* or treatmen* or ray*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	83709
2	nbUVB.mp.	89
3	((narrow band* or narrowband*) and (uvb or ultraviolet*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	1293
4	NB-UVB.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	311

5	uvb.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	7833
6	uv-b.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	3424
7	uv b.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	3424
8	exp Ultraviolet Rays/	66406
9	exp Ultraviolet Therapy/	7409
10	(TL01 or "TL 01" or TL-01 or TLO1).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	177
11	ultraviolet*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	148975
12	exp Phototherapy/ or phototherap*.mp.	32358
13	light therap*.mp.	1429
14	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13	177001
15	exp Psoriasis/ or psoria*.mp.	40423
16	((singl* or doubl* or treb* or tripl*) adj (blind\$3 or mask\$3)).tw.	139993
17	(allocated adj2 random).tw.	745
18	(clin* adj25 trial*).ti,ab.	305021
19	(clinic* adj trial\$1).tw.	245397
20	(double-blind* or random*).af.	1025946
21	clinical trial.pt.	503978
22	clinical trials as topic.sh.	177905
23	clinical* trial*.tw.	245696
24	controlled clinical trial.pt.	91408
25	double blind method.sh.	134117
26	single blind method.sh.	21140
27	double-blind method.sh.	134117
28	single-blind method.sh.	21140
29	drug therapy.fs.	1823349
30	exp clinical trials as topic/	299053
31	exp Research Design/	359477
32	placebo*.tw.	173097
33	placebos.sh.	33846
34	practice guideline.pt.	20628
35	random allocation.sh.	85734
36	random*.ti,ab.	796476
37	random*.tw.	796476
38	Random.af.	273479
39	randomized controlled trial.pt.	408356
40	randomized controlled trials as topic.sh.	101818

41	randomized.ab.	331928
42	randomly allocated.tw.	19471
43	randomly.ab.	239293
44	single-blind method.sh.	21140
45	trial.ab.	345876
46	trial.ti.	146254
47	16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46	3121452
48	case report.tw.	224297
49	letter.pt.	947691
50	historical article.pt.	324199
51	48 or 49 or 50	1483340
52	47 not 51	2929783
53	14 and 15 and 52	2428
54	limit 53 to (danish or english or norwegian or swedish)	1969

Embase

ID	term(s)	results
1	exp psoriasis/ or psoria*.mp.	68931
2	(ultraviolet and (therap* or treatmen* or ray*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	46341
3	ultra violet*.mp.	2181
4	(nbUVB or NB-UVB or UVB or UV-B or UV B).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	14038
5	exp ultraviolet radiation/	96581
6	((narrow band or narrowband) and (uvb or ultraviolet*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	1807
7	(TL01 or "TL 01" or TL-01 or TLO1).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	260
8	exp phototherapy/ or phototherap*.mp.	60877
9	light therap*.mp.	2127
10	2 or 3 or 4 or 5 or 6 or 7 or 8 or 9	171547
11	((singl* or doubl* or treb* or tripl*) adj (blind\$3 or mask\$3)).tw.	178675
12	(allocated adj2 random).tw.	815
13	(clin* adj25 trial*).ti,ab.	404410
14	(clinic* adj trial\$1).tw.	325423
15	(double-blind* or random*).af.	1215545
16	exp "clinical trial (topic)"/	159467
17	exp double blind procedure/ or exp single blind procedure/ or exp triple blind procedure/	144748
18	placebo*.tw.	224177
19	exp placebo/	273859

20	exp randomization/	67598
21	Random.af.	222043
22	random*.tw.	1012040
23	exp "randomized controlled trial (topic)"/	80457
24	randomized.ab.	444501
25	randomly allocated.tw.	23257
26	randomly.ab.	300009
27	trial.ab.	456962
28	trial.ti.	188510
29	exp "controlled clinical trial (topic)"/	83896
30	randomized controlled trial/	382784
31	"randomized controlled trial (topic)"/	80457
32	exp controlled clinical trial/	520653
33	11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32	1863559
34	1 and 10 and 33	1449
35	limit 34 to (conference abstract or editorial)	139
36	34 not 35	1310
37	limit 36 to (danish or english or norwegian or swedish)	1186

PICO 3

Informationskilder

Database	Interface	Dato for søgning
Medline	OVID	30. juni 2015
EMBASE	OVID	30. juni 2015

Medline

ID	term(s)	results
1	methotrexate.mp. or exp Methotrexate/	44722
2	(Methotrexate or Ebetrex or 4 amino 10 methylfolic acid or 4 amino 10 methylpteroylglutamic acid or 4 amino n10 methylpteroylglutamic acid or a methopterin or abitrexate or amethopterin or amethopterin or amethopterin or antifolan or biotrexate or canceren or cl 14377 or cl14377 or emtexate or emthexat or emthexate or emtrexate or enthexate or farmitrexat or farmitrexate or farmotrex or folex or folex pfs or ifamet or imeth or intradose MTX or lantarel or ledertrexate or maxtrex or metex or methoblastin or methohexate or methotrate or methotrexate or methotrexate or methrotrexate or methylaminopterin or methylaminopterin or metical or metoject or metothrexate or metothrexate sodium or metotrexat or methotrexate or metotrexin or metrex or mexate or mexate-aq or mexate-aq preserved or mpi 5004 or mpi5004 or MTX or neotrexate or novatrex or nsc 740 or nsc740 or otrexup or rasuvo or reumatrex or rheumatrex or rheumatrex dose pack or sodium methotrexate or texate or texate-t or texorate or trexall or xaken or zexate).mp. [mp=title, abstract, original title, name of substance word, subject	45939

	heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	
3	1 or 2	45939
4	exp Psoriasis/ or psoria*.mp.	39778
5	acitretin.mp. or exp Acitretin/	1254
6	(etrein or isoacitretin or soriatan or soriatane or neotigason or etretinate free acid or neo-tigason or ro 10 1670 or ro 101670 or ro10 1670 or ro101670).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	107
7	5 or 6	1275
8	((singl: or doubl: or treb: or tripl:) adj (blind:3 or mask:3)).tw.	137139
9	(allocated adj2 random).tw.	729
10	(clin: adj25 trial:).ti,ab.	297096
11	(clinic: adj trial:1).tw.	239402
12	(double-blind: or random:).af.	1003089
13	clinical trial.pt.	496100
14	clinical trials as topic.sh.	173573
15	clinical: trial:.tw.	239689
16	controlled clinical trial.pt.	89802
17	double blind method.sh.	131146
18	single blind method.sh.	20694
19	double-blind method.sh.	131146
20	single-blind method.sh.	20694
21	drug therapy.fs.	1787458
22	exp clinical trials as topic/	291026
23	exp Research Design/	351799
24	placebo:.tw.	169431
25	placebos.sh.	33055
26	practice guideline.pt.	20341
27	random allocation.sh.	83979
28	random:.ti,ab.	779272
29	random:.tw.	779272
30	Random.af.	268374
31	randomized controlled trial.pt.	398895
32	randomized controlled trials as topic.sh.	98593
33	randomized.ab.	325383
34	randomly allocated.tw.	18812
35	randomly.ab.	233811
36	single-blind method.sh.	20694
37	trial.ab.	336904
38	trial.ti.	140728
39	8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38	3058556
40	case report.tw.	221059
41	letter.pt.	886115

42	historical article.pt.	317910
43	40 or 41 or 42	1412819
44	39 not 43	2879186
45	3 and 4 and 7 and 44	126
46	limit 45 to (yr="2012 - 2015" and (danish or english or norwegian or swedish))	34

Embase

ID	term(s)	results
1	exp psoriasis/ or psoria*.mp.	68311
2	exp methotrexate/	139592
3	(Methotrexate or Ebetrex or 4 amino 10 methylfolic acid or 4 amino 10 methylpteroylglutamic acid or 4 amino n10 methylpteroylglutamic acid or a methopterin or abitrexate or amethopterin or amethopterin or ametofterine or antifolan or biotrexate or canceren or cl 14377 or cl14377 or emtexate or emthexat or emthexate or emtrexate or enthexate or farmitrexat or farmitrexate or farmotrex or folex or folex pfs or ifamet or imeth or intradose MTX or lantarel or ledertrexate or maxtrex or metex or methoblastin or methohexate or methotrate or methotrexate or methoxtrexate or methrotrexate or methylaminopterin or methylaminopterin or metical or metoject or methothrexate or metothrexate sodium or metotrexat or methotrexate or metotrexin or metrex or mexate or mexate-aq or mexate-aq preserved or mpi 5004 or mpi5004 or MTX or neotrexate or novatrex or nsc 740 or nsc740 or otrexup or rasuvo or reumatrex or rheumatrex or rheumatrex dose pack or sodium methotrexate or texate or texate-t or texorate or trexall or xaken or zexate).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	144950
4	2 or 3	144950
5	acitretin.mp. or exp etretin/	4740
6	(etretin or isoacitretin or soriatan or soriatane or neotigason or etretinate free acid or neo-tigason or ro 10 1670 or ro 101670 or ro10 1670 or ro101670).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	4655
7	5 or 6	4759
8	((singl: or doubl: or treb: or tripl:) adj (blind:3 or mask:3)).tw.	176949
9	(allocated adj2 random).tw.	810
10	(clin: adj25 trial:).ti,ab.	397814
11	(clinic: adj trial:1).tw.	320298
12	(double-blind: or random:).af.	1198162
13	exp "clinical trial (topic)"/	152869
14	exp double blind procedure/ or exp single blind procedure/ or exp triple blind procedure/	143234
15	placebo:.tw.	221831
16	exp placebo/	271453
17	exp randomization/	66984
18	Random.af.	219179
19	random:.tw.	997917
20	exp "randomized controlled trial (topic)"/	77062

21	randomized.ab.	437933
22	randomly allocated.tw.	22915
23	randomly.ab.	295907
24	trial.ab.	449833
25	trial.ti.	185328
26	8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25	1744846
27	1 and 4 and 7 and 26	339
28	limit 27 to ((danish or english or norwegian or swedish) and yr="2012 - 2015")	122

PICO 4-7

Informationskilder

Database	Interface	Dato for søgning
Medline	OVID	10. juli 2015
EMBASE	OVID	10. juli 2015

Medline

ID	term(s)	results
1	exp Psoriasis/ or psoria*.mp.	40136
2	Salt water bath*.mp.	26
3	Climate therap*.mp.	330
4	exp Climatotherapy/ or Climatotherap*.mp.	648
5	Climatherap*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	3
6	Balneotherap*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	1226
7	Balneology.mp. or exp Balneology/	11278
8	Photoclimatherap*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	2
9	Balneophoterap*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	34
10	Balneo.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	139
11	exp Seawater/ or Sea water*.mp.	33036
12	exp Seawater/ or Seawater*.mp.	36397
13	Spa therap*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	257
14	exp Mineral Waters/ or Mineral water*.mp.	4813

15	Thalassotherap*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	180
16	exp Heliotherapy/ or Heliotherap*.mp.	480
17	((sunlight and (treatment* or therap*))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	3201
18	2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17	58011
19	((singl* or doubl* or treb* or tripl*) adj (blind\$3 or mask\$3)).tw.	139034
20	(allocated adj2 random).tw.	745
21	(clin* adj25 trial*).ti,ab.	300743
22	(clinic* adj trial\$1).tw.	242067
23	(double-blind* or random*).af.	1015629
24	clinical trial.pt.	503065
25	clinical trials as topic.sh.	177305
26	clinical* trial*.tw.	242358
27	controlled clinical trial.pt.	91250
28	double blind method.sh.	133419
29	single blind method.sh.	20951
30	double-blind method.sh.	133419
31	single-blind method.sh.	20951
32	drug therapy.fs.	1812946
33	exp clinical trials as topic/	297514
34	exp Research Design/	357444
35	placebo*.tw.	171745
36	placebos.sh.	33764
37	practice guideline.pt.	20459
38	random allocation.sh.	85312
39	random*.ti,ab.	787396
40	random*.tw.	787396
41	Random.af.	271043
42	randomized controlled trial.pt.	405450
43	randomized controlled trials as topic.sh.	101078
44	randomized.ab.	327890
45	randomly allocated.tw.	19209
46	randomly.ab.	236541
47	single-blind method.sh.	20951
48	trial.ab.	341463
49	trial.ti.	144244
50	19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49	3098075
51	case report.tw.	222310
52	letter.pt.	941820
53	historical article.pt.	322602
54	51 or 52 or 53	1473970

55	50 not 54	2907511
56	1 and 18 and 55	229
57	limit 56 to (danish or english or norwegian or swedish)	174

Embase

ID	term(s)	results
1	exp psoriasis/ or psoria*.mp.	68415
2	salt water bath*.mp.	36
3	Climate therap*.mp.	344
4	Balneology.mp. or exp balneotherapy/	12832
5	Climatherap*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	4
6	exp climatotherapy/ or Climatotherap*.mp.	742
7	exp balneotherapy/ or Balneotherap*.mp.	13058
8	Photoclimatherap*.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	2
9	Balneophototherap*.mp.	70
10	Balneo.mp.	182
11	Sea water*.mp. or exp sea water/	23195
12	Seawater*.mp.	13907
13	Spa therap*.mp.	467
14	Mineral water*.mp. or exp mineral water/	5743
15	exp thalassotherapy/ or Thalassotherap*.mp.	457
16	heliotherap*.mp.	169
17	(sunlight and (treatment* or therap*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	3968
18	2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17	51248
19	((singl* or doubl* or treb* or tripl*) adj (blind\$3 or mask\$3)).tw.	177282
20	(allocated adj2 random).tw.	810
21	(clin* adj25 trial*).ti,ab.	399304
22	(clinic* adj trial\$1).tw.	321398
23	(double-blind* or random*).af.	1201910
24	exp "clinical trial (topic)"/	154136
25	exp double blind procedure/ or exp single blind procedure/ or exp triple blind procedure/	143571
26	placebo*.tw.	222294
27	exp placebo/	271949
28	exp randomization/	67157
29	Random.af.	219731
30	random*.tw.	1001035
31	exp "randomized controlled trial (topic)"/	77743
32	randomized.ab.	439419
33	randomly allocated.tw.	23011
34	randomly.ab.	296871

35	trial.ab.	451502
36	trial.ti.	186109
37	exp "controlled clinical trial (topic)"/	81049
38	randomized controlled trial/	379091
39	"randomized controlled trial (topic)"/	77743
40	exp controlled clinical trial/	516441
41	19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40	1843537
42	1 and 18 and 41	128
43	1 and 18 and 41	128

PICO 8

Informationskilder

Database	Interface	Dato for søgning
Medline	OVID	30. juni 2015
EMBASE	OVID	30. juni 2015

Medline

ID	term(s)	results
1	Cohort studies/	182137
2	comparative study/	1714792
3	follow-up studies/	522093
4	prospective studies/	393782
5	risk factors/	604293
6	cohort.mp.	373050
7	compared.mp.	2467222
8	groups.mp.	1575048
9	multivariate.mp.	252132
10	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9	5657861
11	psoriatic arthritis.mp. or exp Arthritis, Psoriatic/	6302
12	(psoria* adj5 arthrit*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	7374
13	11 or 12	7374
14	screening test*.mp.	24480
15	screening tool*.mp.	12783
16	screening.mp. or exp Mass Screening/	423291
17	screening method*.mp.	13460
18	screening procedure*.mp.	5740
19	screening program*.mp.	21611
20	screening project*.mp.	700
21	(psoriatic arthritis screening and evaluation).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word,	19

	protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	
22	psoriasis epidemiology screening tool.mp.	6
23	toronto psoriatic arthritis.mp.	34
24	alenius classification criteria for psoriatic arthritis.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	0
25	(PASE or PEST or ToPAS or CASPAR).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	20636
26	toronto mass screening.mp.	0
27	(screen* adj tool*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	12803
28	(evaluat* and tool*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	121676
29	psoriatic arthritis screening.mp.	28
30	(classification criteria and psoriatic arthritis).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	146
31	exp Mass Screening/ or health screening.mp.	106345
32	14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31	552415
33	disease progression.mp. or exp Disease Progression/	161996
34	exp Prognosis/ or prognos*.mp.	1365958
35	incidence.mp. or exp Incidence/	634271
36	prevalence.mp. or exp Prevalence/	488527
37	exp Time Factors/ or time factor*.mp.	1038212
38	exp Natural History/ or natural histor*.mp.	39072
39	joint assessmen*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	215
40	tender joint count.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	324
41	swollen joint count.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	410
42	(DAS28 or ACR20 or ACR50 or ACR70).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	2368
43	33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42	3267156

44	10 and 13 and 32 and 43	114
45	limit 44 to (yr="2005 - 2015" and (danish or english or norwegian or swedish))	88

Embase

ID	term(s)	results
1	psoriatic arthritis.mp. or exp psoriatic arthritis/	13923
2	(psoria* adj5 arthrit*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	15411
3	1 or 2	15411
4	exp screening test/ or Screening test*.mp.	71645
5	Screening tool*.mp.	19017
6	Screening.mp. or exp screening/	732259
7	screening method*.mp.	19475
8	screening procedure*.mp.	7041
9	screening program*.mp.	28927
10	screening programme*.mp.	9580
11	screening project*.mp.	912
12	(psoriatic arthritis screening and evaluation).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	37
13	psoriasis epidemiology screening tool.mp.	14
14	toronto psoriatic arthritis.mp.	54
15	alenius classification criteria for psoriatic arthritis.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	0
16	(PASE or PEST or ToPAS or CASPAR).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	23907
17	toronto mass screening.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	0
18	(screen* adj tool*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	19053
19	(evaluat* and tool*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	166974
20	psoriatic arthritis screening.mp.	52
21	(classification criteria and psoriatic arthritis).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	323
22	health screening.mp. or exp mass screening/	173242
23	mass screening*.mp.	53584
24	4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23	904001
25	disease progression.mp. or exp disease course/	2251351

26	exp prognosis/ or Prognosis.mp.	642097
27	prognos*.mp.	758386
28	exp incidence/ or incidence.mp.	840015
29	prevalence.mp. or exp prevalence/	681944
30	time factor*.mp.	2319
31	natural histor*.mp.	50276
32	Joint assessment*.mp.	359
33	Tender Joint count.mp.	842
34	Swollen joint count.mp.	1073
35	(DAS28 or ACR20 or ACR50 or ACR70).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	8364
36	25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35	3636343
37	Clinical article/	1494929
38	controlled study/	4645554
39	major clinical study/	2360756
40	prospective study/	296617
41	cohort.mp.	487810
42	compared.mp.	3173052
43	groups.mp.	1979691
44	multivariate.mp.	318479
45	37 or 38 or 39 or 40 or 41 or 42 or 43 or 44	9566045
46	3 and 24 and 36 and 45	472
47	limit 46 to (yr="2005 - 2015" and (danish or english or norwegian or swedish))	429

PICO 9

Informationskilder

Database	Interface	Dato for søgning
Medline	OVID	7. juli 2015
EMBASE	OVID	7. juli 2015

Medline

ID	term(s)	results
1	exp Psoriasis/ or psoria*.mp.	39839
2	exp Cardiovascular Diseases/ or cardiovascular disease*.mp.	1994193
3	exp Hypertension/ or hypertens*.mp.	406050
4	(essential adj hypertension).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	20846
5	(isolat* adj hypertension).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	55

6	(elevat* adj2 blood adj pressur*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	8140
7	(high adj blood adj pressur*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	11381
8	(increase* adj2 blood pressur*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	15565
9	((systolic or diastolic or arterial) adj2 pressur*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	152798
10	exp Myocardial Infarction/ or heart infarction*.mp.	151338
11	exp Myocardial Infarction/ or myocardial infarct*.mp.	206237
12	((cardiac or heart) adj (infarct* or attack* or arrest* or event*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	60106
13	exp Heart Failure/ or heart failure*.mp.	148521
14	exp Heat Stroke/ or stroke*.mp.	202864
15	cerebrovascular accident*.mp.	5476
16	(stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident").mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	208354
17	((cerebro* or brain or brainstem or cerebral\$) adj3 (infarct\$ or accident\$)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]	46501
18	exp Dyslipidemias/ or dyslipidemia*.mp.	77384
19	2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18	2310625
20	1 and 19	2131
21	((singl* or doubl* or treb* or tripl*) adj (blind\$3 or mask\$3)).tw.	137213
22	(allocated adj2 random).tw.	728
23	(clin* adj25 trial*).ti,ab.	297458
24	(clinic* adj trial\$1).tw.	239677
25	(double-blind* or random*).af.	1004001
26	clinical trial.pt.	496174
27	clinical trials as topic.sh.	173607
28	clinical* trial*.tw.	239966
29	controlled clinical trial.pt.	89829
30	double blind method.sh.	131189

31	single blind method.sh.	20710
32	double-blind method.sh.	131189
33	single-blind method.sh.	20710
34	drug therapy.fs.	1788414
35	exp clinical trials as topic/	291170
36	exp Research Design/	351980
37	placebo*.tw.	169546
38	placebos.sh.	33060
39	practice guideline.pt.	20360
40	random allocation.sh.	84044
41	random*.ti,ab.	780082
42	random*.tw.	780082
43	Random.af.	268620
44	randomized controlled trial.pt.	399134
45	randomized controlled trials as topic.sh.	98693
46	randomized.ab.	325685
47	randomly allocated.tw.	18833
48	randomly.ab.	234080
49	single-blind method.sh.	20710
50	trial.ab.	337238
51	trial.ti.	140880
52	21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51	3060604
53	case report.tw.	221168
54	letter.pt.	886378
55	historical article.pt.	317993
56	53 or 54 or 55	1413275
57	52 not 56	2881143
58	Cohort studies/	182273
59	comparative study/	1715228
60	follow-up studies/	522308
61	prospective studies/	394025
62	risk factors/	604643
63	cohort.mp.	373468
64	compared.mp.	2469544
65	groups.mp.	1576113
66	multivariate.mp.	252259
67	58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66	5661571
68	57 or 67	7326001
69	20 and 68	1293
70	limit 69 to (yr="2012 - 2015" and (danish or english or norwegian or swedish))	426

Embase

ID	term(s)	results
1	exp psoriasis/ or psoria*.mp.	68367

2	cardiovascular diseases/	173627
3	cardiovascular disease*.mp. or exp cardiovascular disease/	3239738
4	exp hypertension/ or hypertens*.mp.	726511
5	(essential adj hypertension).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	35175
6	(isolat* adj hypertension).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	84
7	(elevat* adj2 blood adj pressur*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	11597
8	(high adj blood adj pressur*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	15956
9	(increase* adj2 blood pressur*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	19270
10	((systolic or diastolic or arterial) adj2 pressur*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	250322
11	exp heart infarction/ or myocardial infarct*.mp.	328572
12	((cardiac or heart) adj (infarct* or attack* or arrest* or event*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	344072
13	heart failure.mp. or exp heart failure/	370029
14	stroke*.mp. or exp cerebrovascular accident/	327088
15	(stroke or strokes or cva or poststroke* or apoplexy or "cerebrovascular accident").mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	331922
16	((cerebro* or brain or brainstem or cerebral\$) adj3 (infarct\$ or accident\$)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]	156812
17	dyslipidemia*.mp. or exp dyslipidemia/	49428
18	2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17	3486827
19	((singl* or doubl* or treb* or tripl*) adj (blind\$3 or mask\$3)).tw.	177176
20	(allocated adj2 random).tw.	810
21	(clin* adj25 trial*).ti,ab.	398871
22	(clinic* adj trial\$1).tw.	321071
23	(double-blind* or random*).af.	1200898
24	exp "clinical trial (topic)"/	153656
25	exp double blind procedure/ or exp single blind procedure/ or exp triple blind procedure/	143447
26	placebo*.tw.	222157
27	exp placebo/	271775
28	exp randomization/	67141
29	Random.af.	219608

30	random*.tw.	1000251
31	exp "randomized controlled trial (topic)"/	77457
32	randomized.ab.	439026
33	randomly allocated.tw.	22983
34	randomly.ab.	296630
35	trial.ab.	451111
36	trial.ti.	185900
37	exp "controlled clinical trial (topic)"/	80746
38	randomized controlled trial/	378749
39	"randomized controlled trial (topic)"/	77457
40	exp controlled clinical trial/	516057
41	19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40	1842081
42	Clinical article/	1495982
43	controlled study/	4650832
44	major clinical study/	2362958
45	prospective study/	297576
46	cohort.mp.	489489
47	compared.mp.	3179621
48	groups.mp.	1983774
49	multivariate.mp.	319471
50	42 or 43 or 44 or 45 or 46 or 47 or 48 or 49	9580278
51	41 or 50	10203736
52	1 and 18 and 51	4425
53	limit 52 to ((danish or english or norwegian or swedish) and yr="2012 - 2015")	1874
54	limit 53 to (conference abstract or editorial)	590
55	53 not 54	1284